Additionally, in a randomized, double-blind, placebo-controlled trial, EOS counts and EOS% in induced sputum were markedly reduced after 16 weeks of roflumilast (a PDE4 inhibitor) treatment in COPD [39]. This evidence concerns the gene PDE4A and chronic obstructive pulmonary disease.